High Spy1 expression predicts poor prognosis in colorectal cancer
Authors Jin Q, Liu G, Bao L, Ma Y, Qi H, Yun Z, Dai Y, Zhang S
Received 26 March 2018
Accepted for publication 28 May 2018
Published 16 August 2018 Volume 2018:10 Pages 2757—2765
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Professor Nakshatri
Qin Jin,1,* Gang Liu,2,* Luri Bao,3,* Yuzhen Ma,4 Huidong Qi,5 Zhizhong Yun,4 Yanfeng Dai,2 Shu Zhang1
1Department of Pathology, Affiliated Hospital of Nantong University, Nantong, People’s Republic of China; 2State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, College of Life Science, Inner Mongolia University, Hohhot, People’s Republic of China; 3Department of Pathology, Inner Mongolia Medical University, Hohhot, People’s Republic of China; 4Centre of Reproductive Medicine, Inner Mongolia Hospital, Hohhot, People’s Republic of China; 5Medical School of Nantong University, Nantong, People’s Republic of China
*These authors contributed equally to this work
Background: Spy1 (SPDYA) is a new discovered cell cycle protein capable of promoting cell proliferation dependent on cyclin-dependent kinase-2 activation. However, to the best of our knowledge, the expression of Spy1 in colorectal cancer (CRC) tissues remains virtually unknown.
Materials and methods: In this retrospective study, we investigated the mRNA and protein expression levels of Spy1 in CRC tissues and corresponding non-cancerous tissues with the analyses of quantitative real-time polymerase chain reaction, western blotting, and immunohistochemistry. In our research, the prognostic significances of Spy1 expression were further explored by univariate and multivariate survival analyses of 203 patients who were followed up.
Results: The results demonstrated that the levels of Spy1 mRNA were significantly higher in CRC tissues compared with corresponding non-cancerous tissues (p=0.0002). The results of immunohistochemistry demonstrated that the expressions of Spy1 were significantly associated with clinicopathological parameters, including T stage (χ2=7.126, p=0.028) and TNM stage (χ2=9.461, p=0.009). Kaplan-Meier analysis results indicated that high Spy1 expression (HR=2.573, p<0.001) and TNM stage (HR=1.494, p=0.011) were independent factors to predict poor prognosis for patients with CRC.
Conclusion: We concluded that high Spy1 expression is significantly associated with unfavorable prognosis in CRC and could serve as a potential prognostic marker in clinical diagnosis of CRC.
Keywords: Spy1, colorectal cancer, prognostic marker, clinical diagnosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]